1. Introduction {#sec1-antibiotics-07-00041}
===============

The *Streptomyces* genus includes an important group of biotechnological bacteria. They produce two-thirds of the antibiotics of medical and agricultural interest, several antitumor agents, antifungals, and a great number of eukaryotic cell differentiation effectors, such as apoptosis inducers and inhibitors \[[@B1-antibiotics-07-00041]\]. Drug discovery from *streptomycetes* fell considerably after initial screenings where the most common compounds were discovered. Antibiotic resistance is increasing dramatically, and new antibiotics are urgently required in the clinic. Alternative methods, such as the exploration of chemical libraries and combinatorial chemistry, have provided limited yields. Screening from nature has resumed through methods such as exploring new environments, looking for elicitors, accessing the metagenome, etc.

One of the most important characteristics of *Streptomyces* is its complex life cycle, which is closely related to secondary metabolite production \[[@B2-antibiotics-07-00041]\] (outlined in [Figure 1](#antibiotics-07-00041-f001){ref-type="fig"}). In solid sporulating cultures, development starts with spore germination and the rapid development of compartmentalised hyphae into the medium (early substrate mycelium or MI) \[[@B3-antibiotics-07-00041]\]. After that, programmed cell death (PCD) occurs (red cellular segments in [Figure 1](#antibiotics-07-00041-f001){ref-type="fig"}) which triggers the differentiation of the multinucleated (MII) antibiotic-producing hyphae (late substrate mycelium, early MII) \[[@B3-antibiotics-07-00041],[@B4-antibiotics-07-00041]\]. Then, the mycelium starts to grow into the air forming the aerial mycelium (late MII). At the end of the cycle, there is a second round of PCD, and most of the remaining viable hyphae undergo a process of compartmentalisation that culminates in the formation of unigenomic spores \[[@B5-antibiotics-07-00041]\].

Most *streptomycetes* do not sporulate in liquid cultures. Therefore, it was previously assumed that under these conditions, there was no differentiation. However, industrial antibiotic production is mostly performed in liquid cultures (flasks and bioreactors). Currently, it is known that in liquid cultures, differentiation is comparable to that observed in solid cultures ([Figure 1](#antibiotics-07-00041-f001){ref-type="fig"}). In liquid cultures, there is a first mycelium stage (MI), PCD and the differentiation of a secondary metabolite, producing mycelium (MII). However, in most *Streptomyces* strains, aerial mycelium formation and sporulation are blocked \[[@B6-antibiotics-07-00041]\] ([Figure 1](#antibiotics-07-00041-f001){ref-type="fig"}). *S. coelicolor* proteomic and transcriptomic studies have shown that physiological differentiation in liquid and solid cultures is comparable \[[@B6-antibiotics-07-00041],[@B7-antibiotics-07-00041]\]. MII expresses/translates the genes/proteins involved in secondary metabolism in both solid and liquid cultures \[[@B6-antibiotics-07-00041],[@B7-antibiotics-07-00041]\].

Surprisingly, *Streptomyces* differentiation as a trigger for antibiotic production remains almost unexplored. The absence of a developmental model to describe differentiation in liquid cultures has inhibited the understanding of the relationship between macroscopic morphology (pellet and clump formation) and differentiation. Pellet and clump formation has been classically correlated with secondary metabolite production, but the relationship between both processes remains obscure. Most authors have affirmed that pellets and clumps are fundamental for secondary metabolite production (e.g., retamycin in *S. olindensis* \[[@B8-antibiotics-07-00041]\], nikkomycins in *S. tendae* \[[@B9-antibiotics-07-00041]\], hybrid antibiotics in *S. lividans* \[[@B10-antibiotics-07-00041]\]), while some authors have affirmed that pellet and clump formation reduces antibiotic production (e.g., nystatin in *S. noursei* \[[@B11-antibiotics-07-00041]\], tylosin in *S. fradiae* \[[@B12-antibiotics-07-00041]\]). More recently, our group demonstrated that one of the key events in the activation of secondary metabolite production in *Streptomyces* liquid cultures is the differentiation of MII (e.g., actinorhodin/undecylprodigiosin production in *S. coelicolor* \[[@B2-antibiotics-07-00041],[@B13-antibiotics-07-00041]\], microbial transglutaminase production in *S. mobarensis* \[[@B14-antibiotics-07-00041]\], apigenin and luteolin production in *S. albus* \[[@B15-antibiotics-07-00041]\]). The differentiation of this mycelium is conditioned by PCD of the vegetative hyphae (MI) \[[@B2-antibiotics-07-00041]\], which, in liquid cultures, depends on the growth rate of the strain and hypha aggregation (pellet/clump formation) \[[@B2-antibiotics-07-00041],[@B7-antibiotics-07-00041],[@B14-antibiotics-07-00041],[@B15-antibiotics-07-00041],[@B16-antibiotics-07-00041]\]. However, secondary metabolism has additional regulations (elicitors activate specific biosynthetic pathways) \[[@B17-antibiotics-07-00041]\], and most *Streptomyces* strains do not display all their potential secondary metabolites under standard developmental laboratory conditions, even if they are differentiated at the MII stage \[[@B7-antibiotics-07-00041]\].

Each *Streptomyces* strain can harbour up to 30 secondary metabolite pathways, but only a few of these are active in usual screening processes \[[@B18-antibiotics-07-00041]\]. Activating these pathways in the lab will be crucial in the process of screening for new secondary metabolites from actinomycetes. Here, we review the most important strategies that are being explored to activate cryptic pathways and/or those that are being explored to enhance secondary metabolites production.

2. Screening for New Secondary Metabolites from *Streptomycetes* {#sec2-antibiotics-07-00041}
================================================================

The search for new actinomycetes in unexplored niches or from the screening of strains that have not been previously cultivated is useful, but usually leads to the rediscovery of already known compounds \[[@B19-antibiotics-07-00041]\]. New screening strategies are necessary to overcome the current challenges of discovering new bioactive compounds \[[@B19-antibiotics-07-00041]\]. In 2013, Arryn Craney et al. \[[@B20-antibiotics-07-00041]\] summarised the new strategies that are being used to enhance secondary metabolite production and activate cryptic pathways, dividing them into unselective and selective methods \[[@B20-antibiotics-07-00041]\]. Unselective methods are non-specific methods that are used to screen for new activities, whereas selective methods are biosynthetic cluster-specific methods that are used to improve the production of already known molecules \[[@B20-antibiotics-07-00041]\].

Non-specific methods were largely used during "the golden age of antibiotics", and they are still useful. These methods include classical strategies, such as changing media components, increasing general precursors (metabolic engineering), inducing stress responses (with heat/ethanol/salt/acid shock, nutrient limitations) \[[@B21-antibiotics-07-00041]\], and obtaining strains that overproduce secondary metabolites by random mutagenesis \[[@B22-antibiotics-07-00041],[@B23-antibiotics-07-00041],[@B24-antibiotics-07-00041]\]. More novel non-specific methods include ribosomal engineering (the alteration of ribosomal proteins to activate cryptic secondary metabolites in *streptomycetes*) \[[@B20-antibiotics-07-00041],[@B25-antibiotics-07-00041]\] and the use of small molecules as elicitors of secondary metabolism \[[@B20-antibiotics-07-00041],[@B26-antibiotics-07-00041]\] ([Table 1](#antibiotics-07-00041-t001){ref-type="table"}). Differentiation of the antibiotic producer mycelium (MII) as a non-specific method to activate antibiotic production remains almost unexplored. There has been no previous analysis of the frequency of *Streptomyces* strains that do not produce secondary metabolites because they are not differentiated at the MII stage in the laboratory.

Biosynthetic cluster-specific methods include self-resistance engineering (upregulation of self-resistance genes), regulatory engineering (overexpression of activators or elimination of repressors) and genome mining to search for new biosynthetic pathways \[[@B20-antibiotics-07-00041]\] ([Table 2](#antibiotics-07-00041-t002){ref-type="table"}). One of the most important biosynthetic cluster-specific methods is heterologous expression. Heterologous expression has been used to express *Streptomyces* industrial enzymes, such as laccases, in microorganisms with simpler developmental cycles than *Streptomyces*, such as *E. coli* \[[@B27-antibiotics-07-00041]\]. However, the complex biosynthetic pathways of *Streptomyces* rarely can be expressed in simple expression hosts, such as *E. coli* or *Bacillus*. Thus, other *streptomycetes*, such as *S. lividans*, *S. albus*, *S. coelicolor* or *S. avermitilis*, are commonly used as expression hosts \[[@B28-antibiotics-07-00041]\]. The activation of cryptic metabolites through the expression of the *Streptomyces coelicolor* pleiotropic regulator, *Afs*Q, in other *streptomycetes* \[[@B29-antibiotics-07-00041]\] has been successfully achieved. Combinatorial biosynthesis, chemical modification of existing molecules, has been largely developed over the last 20 years, in particular, progress has been made in the last few years thanks to genome mining and synthetic biology \[[@B30-antibiotics-07-00041],[@B31-antibiotics-07-00041],[@B32-antibiotics-07-00041]\]. Differentiation of *Streptomyces* MII was successfully used to enhance the production of various products \[[@B2-antibiotics-07-00041],[@B13-antibiotics-07-00041],[@B14-antibiotics-07-00041],[@B15-antibiotics-07-00041]\] through its role as a trigger for antibiotic production (described in [Section 2.3](#sec2dot3-antibiotics-07-00041){ref-type="sec"}).

2.1. Streptomyces Differentiation Strategies Based on Elicitors {#sec2dot1-antibiotics-07-00041}
---------------------------------------------------------------

In the last few years, effort has been made to elucidate the mechanism by which some small molecules (elicitors) affect differentiation and secondary metabolite production in *Streptomyces* strains. Elicitors can be defined as diffusible signals that are able to induce cryptic pathways and/or differentiation in *Streptomyces* cultures \[[@B17-antibiotics-07-00041]\]. Some elicitors act as signals for interspecies interaction \[[@B33-antibiotics-07-00041]\]. Thus, subinhibitory concentrations of certain antibiotics produced by a given *Streptomyces* strain accelerate differentiation and antibiotic production in other *Streptomyces* strains through "pseudo" gamma-butyrolactone receptors \[[@B33-antibiotics-07-00041]\]. Another good strategy is the use of random chemical probes (natural or synthetic) as elicitors (reviewed in \[[@B21-antibiotics-07-00041]\]).

One of the most common strategies used to activate secondary metabolism and differentiation is mimicking the ecological environment through co-cultures of different microbes \[[@B17-antibiotics-07-00041],[@B34-antibiotics-07-00041]\]. This methodology typically uses species that have symbiotic relationships with *Streptomyces* in nature \[[@B35-antibiotics-07-00041],[@B36-antibiotics-07-00041]\] or pathogen partners that activate the production of antimicrobial compounds \[[@B37-antibiotics-07-00041],[@B38-antibiotics-07-00041],[@B39-antibiotics-07-00041]\]. For instance, fungal elicitors (complex mix of cell walls and filtered cultures) positively affect the production of natamycin \[[@B40-antibiotics-07-00041]\], bacterial and yeast elicitors improve valinomycin production \[[@B41-antibiotics-07-00041]\], nutrients such as glucose and xylose repress the production of actinorhodin \[[@B42-antibiotics-07-00041],[@B43-antibiotics-07-00041]\], and small molecules, such as GlcNAc or phosphate, can trigger differentiation and antibiotic production in *S. coelicolor* through the activation of *act*II-ORF4/*red*Z genes \[[@B44-antibiotics-07-00041]\].

Pimentel-Elardo et al. \[[@B45-antibiotics-07-00041]\] developed an activity-independent screening method based on the use of elicitors, to prevent the rediscovery of the most active/abundant compounds. In addition, cheminformatics techniques are used to identify the putative biological activities of identified compounds \[[@B45-antibiotics-07-00041]\]. The use of elicitors increases the production of low-abundant compounds which were undetected in the classical activity dependent screening. The chemical elicitor "CI-ARC" has been identified as being responsible for triggering several cryptic biosynthetic genes \[[@B45-antibiotics-07-00041]\].

2.2. Differentiation Strategies Based on Macroscopic Morphology {#sec2dot2-antibiotics-07-00041}
---------------------------------------------------------------

### 2.2.1. The Genetic Control of Aggregation and Macroscopic Morphology in Liquid Cultures {#sec2dot2dot1-antibiotics-07-00041}

Large-scale antibiotic production is mostly performed in liquid cultures. It is almost unanimously accepted that the macroscopic morphology of the mycelium (pellets and clump formation) is correlated with the production of secondary metabolites. However, it was not until recently that the genes controlling pellet and clump formation have been characterised. The *S. coelicolor mat* gene cluster \[[@B46-antibiotics-07-00041]\] and the *cslA*, *glxA*, *dtpA* genes \[[@B47-antibiotics-07-00041],[@B48-antibiotics-07-00041],[@B49-antibiotics-07-00041]\] are responsible for mycelial aggregation and pellet formation. These genes could be a great tool for controlling the morphology in industrial fermentation.

The *Streptomyces* life cycle in liquid cultures starts with the germination of spores. Awakening from the dormant spore state depends on the level of AMPc in the cultures \[[@B50-antibiotics-07-00041]\] and involves the small hydrophobic protein NepA, \[[@B51-antibiotics-07-00041]\]. The expression of several sigma factors involved in osmotic and oxidative stress (SigH, SigB, SigI, SigJ) undergoes remarkable changes during germination, indicating that germination evokes stress-like cell responses \[[@B52-antibiotics-07-00041]\]. Several genes encoding proteins involved in lipid metabolism and membrane transport are overexpressed during germination \[[@B52-antibiotics-07-00041]\]. The conservation of [d]{.smallcaps}-alanyl-[d]{.smallcaps}-alanine carboxypeptidase (SCO4439) contributes to the swelling phase of germination \[[@B53-antibiotics-07-00041]\]. Cell wall hydrolases participate in germination \[[@B54-antibiotics-07-00041]\]. SsgA protein marks the germinative tube emission points \[[@B55-antibiotics-07-00041]\]. Recently it was described that during germination, spores aggregate due to extracellular glycans synthesized by the MatA, MatB \[[@B46-antibiotics-07-00041],[@B56-antibiotics-07-00041]\] and the CslA/GlxA/DtpA proteins \[[@B56-antibiotics-07-00041]\]. These aggregates determine the macroscopic morphology (pellets and clumps) of the culture \[[@B56-antibiotics-07-00041]\] which triggers PCD and the physiological differentiation of the antibiotic producer, mycelium MII \[[@B2-antibiotics-07-00041]\].

Another issue that influence secondary metabolite production is sporulation. Several *streptomycetes* are able to sporulate in liquid cultures \[[@B57-antibiotics-07-00041]\] and some strains, that normally do not sporulate are also able to sporulate in bioreactors due to the stress generated in the fermenter \[[@B13-antibiotics-07-00041]\]. Sporulation stops metabolism, including secondary metabolite production. Consequently, in industrial fermentations and during screening for new secondary metabolites, it is important to avoid sporulation to increase and maintain secondary metabolism for as long as possible \[[@B13-antibiotics-07-00041]\].

### 2.2.2. Monitoring of *Streptomyces* Macroscopic Morphology and Differentiation in Liquid Cultures {#sec2dot2dot2-antibiotics-07-00041}

Pellet and clump formation led to differentiation and secondary metabolism \[[@B2-antibiotics-07-00041]\]. Consequently, new methodologies to monitor macroscopic morphology have been developed. Laser diffraction has been used to measure pellet size \[[@B58-antibiotics-07-00041]\]. Flow cytometry has been used to establish pellet size distribution of culture populations \[[@B59-antibiotics-07-00041],[@B60-antibiotics-07-00041]\]. Recently, a useful algorithm was developed as a plug-in for the open-source software, ImageJ, to characterize the morphology of filamentous microorganisms in liquid cultures \[[@B61-antibiotics-07-00041]\]. Mathematical models have been performed to predict the behaviour of *Streptomyces* liquid cultures based on pellet/clump morphology \[[@B62-antibiotics-07-00041],[@B63-antibiotics-07-00041]\].

Biophysical parameters (e.g., pH, viscosity, agitation, dissolved oxygen levels and surface tension, among others) directly affect morphology and differentiation \[[@B13-antibiotics-07-00041],[@B64-antibiotics-07-00041]\]. These parameters must be considered when scaling up production to industrial conditions \[[@B65-antibiotics-07-00041]\]. Interestingly, a recent study downscaled liquid cultures to the 100 µL scale in microtiter plates \[[@B66-antibiotics-07-00041]\], reproducing the same range of production and morphology as large-scale bioreactors, making screening easier and facilitating further upscaling.

### 2.2.3. Macroscopic Morphology Conditions, Programmed Cell Death and Second Mycelium Differentiation in Liquid Cultures {#sec2dot2dot3-antibiotics-07-00041}

PCD is the key event that triggers the differentiation of the antibiotic producer, mycelium (MII), in liquid and solid cultures \[[@B2-antibiotics-07-00041]\]. However, the specific signals derived from cell death are not yet known. The production of *N*-acetylglucosamine from peptidoglycan dismantling accelerates development and antibiotic production \[[@B67-antibiotics-07-00041],[@B68-antibiotics-07-00041]\] and might be one of the signals released during PCD.

A simple methodology based on fluorometric measures of cultures stained with SYTO9 and propidium iodide was designed to quantify PCD in liquid cultures \[[@B69-antibiotics-07-00041]\]. This method allows the efficiency of antibiotic production to be predicted based on the level of PCD \[[@B69-antibiotics-07-00041]\].

Strains showing dispersed growth take a long time to suffer PCD, and sometimes, PCD does not occur. Modify the developmental conditions to enhance PCD and MII differentiation, leads to an improvement in secondary metabolite production. This approach was recently applied to enhance flavonoid production in a strain of *Streptomyces albus* \[[@B15-antibiotics-07-00041]\] and to enhance microbial transglutaminase production from *Streptomyces mobaraensis* \[[@B14-antibiotics-07-00041]\]. The "PCD-MII" approach complements other approaches well; there is no secondary metabolite production without differentiation of MII, but there are biosynthetic pathways that in addition to MII differentiation, need specific elicitors to become active \[[@B70-antibiotics-07-00041]\].

2.3. L-Forms {#sec2dot3-antibiotics-07-00041}
------------

An interesting alternative that would avoid the problems of mycelial growth in industry, is the use of L-forms, which are individual cells without cell walls \[[@B71-antibiotics-07-00041]\]. However, until now, the antibiotic levels reached by *Streptomyces* L-forms have been quite minor compared to those reached by the regular form. Therefore, future research should explore whether L-forms could offer an industrial alternative.

2.4. Other Strategies {#sec2dot4-antibiotics-07-00041}
---------------------

A big challenge in screening for new secondary metabolites is exploring non-cultivated bacteria. The scientific community is aware of the huge quantity of microorganisms that are not cultivated under laboratory conditions. Next Generation Sequencing revealed the big pharmacological potential of uncultured bacteria. Innovative culturing techniques, such as the isolation chip (iChip), are being used successfully in combination with co-cultures to grow previously uncultured bacteria \[[@B72-antibiotics-07-00041]\]. The study of unexplored niches to look for new Actinomycetes is another strategy that enables the discovery of new species and compounds \[[@B73-antibiotics-07-00041],[@B74-antibiotics-07-00041],[@B75-antibiotics-07-00041]\]. The combination of these two methods is a promising strategy to identify new compounds.

One of the newest strategies focusses on primary metabolism and vegetative growth. Very recently, work by Schniete et al. \[[@B76-antibiotics-07-00041]\] showed how genetic redundancy within actinobacterial genomes allows functional specialization of two pyruvate kinases in *Streptomyces* under different life cycle stages and environmental conditions. Genetic redundancy within actinobacteria genomes as being a key to understanding how the plasticity of this microorganism enhances the production of clinically useful molecules. Furthermore, Cihak et al. \[[@B77-antibiotics-07-00041]\] recently described the production of secondary metabolites during germination in *Streptomyces coelicolor*. The germination stage was ignored in most secondary metabolite screening campaigns and constitutes a potential source of bioactive compounds to be explored \[[@B77-antibiotics-07-00041]\].

3. Conclusions {#sec3-antibiotics-07-00041}
==============

We generally face the great challenge of fighting antibiotic resistance, which is growing much faster than our capacity to find new antimicrobials and new strategies to face this problem. The *Streptomyces* genus is still a huge source of natural bioactive compounds, but we need to form new strategies to avoid rediscovering compounds. There is not a single methodology to trigger differentiation, activate cryptic secondary metabolism pathways and improve the discovery of new bioactive compounds. However, the multidisciplinary biosynthetic cluster specific and non-specific approaches discussed in this manuscript, will be key to improving the screening for new secondary metabolites from *streptomycetes*.
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![*Streptomyces* growth in solid cultures (**upper panels**) and liquid cultures (**lower panels**). In solid cultures (petri plates), spores germinate developing a compartmentalised mycelium (early substrate mycelium, MI) with 1 µm average cross-membrane spacing \[[@B6-antibiotics-07-00041]\]. Some of the MI cells suffer a first round of programmed cell death PCD (red segments). The remaining viable segments start to grow as a multinucleated mycelium with sporadic septa (early MII, late substrate mycelium) \[[@B6-antibiotics-07-00041]\]. The mycelium substrate suffers a second round of PCD (red segments) and differentiates into a mycelium that starts to grow into the air (the medium/agar border is indicated by a brown line) (late MII, aerial mycelium). Part of the aerial hyphae form spore chains (black circles). In liquid cultures, there is germination, MI development, PCD (in the centre of the mycelial pellets) and MII differentiation (in the periphery of the pellets). In most species, there is no aerial mycelium formation or sporulation, and hyphae form pellets and clumps \[[@B2-antibiotics-07-00041]\]. Secondary metabolites (outlined as yellow circles and blue starts) are produced by the MII hyphae.](antibiotics-07-00041-g001){#antibiotics-07-00041-f001}

antibiotics-07-00041-t001_Table 1

###### 

Non-specific methods and some successful examples of their enforcement. "Enhance" means an improvement in production; "cryptic" means activation of the expression of cryptic pathways.

  Methods                                   Microorganism                      Product                                                   Effect                            Ref.
  ----------------------------------------- ---------------------------------- --------------------------------------------------------- --------------------------------- ---------------------------------
  **Media manipulation**                    *S. roseosporus*                   Daptomycin                                                Enhance                           \[[@B78-antibiotics-07-00041]\]
  **Stress Response**                       *S. venezuelae*                    Jadomycin B                                               Enhance                           \[[@B79-antibiotics-07-00041]\]
  *S. hygroscopicus*                        Validamycin A                      Enhance                                                   \[[@B21-antibiotics-07-00041]\]   
  *S. parvulus*                             Manumycin family                   Cryptic                                                   \[[@B80-antibiotics-07-00041]\]   
  *S. coelicolor*                           Ectoine, 5-hydroxyectoine          Enhance                                                   \[[@B81-antibiotics-07-00041]\]   
  *S. coelicolor*                           Methylenomycin                     Enhance                                                   \[[@B82-antibiotics-07-00041]\]   
  **One Strain Many Compounds (OSMAC)**     *S. parvulus*                      20 cryptic compounds                                      Cryptic                           \[[@B80-antibiotics-07-00041]\]
  **Random Mutagenesis**                    *S. clavuligerus*                  Clavulanic acid                                           Enhance                           \[[@B83-antibiotics-07-00041]\]
  *S. hygroscopicus*                        Rapamycin                          Enhance                                                   \[[@B84-antibiotics-07-00041]\]   
  *S. coelicolor*                           Actinorhodin, Undecylprodigiosin   Enhance                                                   \[[@B22-antibiotics-07-00041]\]   
  **Ribosomal Engineering**                 *S. coelicolor*                    Actinorhodin                                              Enhance                           \[[@B85-antibiotics-07-00041]\]
  **Engineering Global Regulation**         *S. coelicolor*                    Actinorhodin, Prodigiosin, Calcium-Dependent Antibiotic   Enhance                           \[[@B86-antibiotics-07-00041]\]
  *S. griseus*                              Streptomycin                       Enhance                                                   \[[@B86-antibiotics-07-00041]\]   
  *S. griseochromogenes*                    Blasticidin S                      Enhance                                                   \[[@B86-antibiotics-07-00041]\]   
  **Elicitors**                             *S. coelicolor*                    Actinorhodin                                              Enhance                           \[[@B87-antibiotics-07-00041]\]
  *S. pristinaespiralis*                    Desferrioxamine B/E                Enhance                                                   \[[@B20-antibiotics-07-00041]\]   
  *S. peucetius*                            Doxorubicin, Baumycin              Enhance                                                   \[[@B20-antibiotics-07-00041]\]   
  *S. coelicolor*                           Actinorhodin, Undecylprodigiosin   Enhance                                                   \[[@B68-antibiotics-07-00041]\]   
  *S. lividans*                             Prodiginine                        Enhance                                                   \[[@B88-antibiotics-07-00041]\]   
  *S. griseus*                              Streptomycin                       Enhance                                                   \[[@B21-antibiotics-07-00041]\]   
  *S. natalensis*                           Pimaricin                          Enhance                                                   \[[@B89-antibiotics-07-00041]\]   
  29 strains                                Cryptic compounds                  Cryptic                                                   \[[@B45-antibiotics-07-00041]\]   
  **Metabolic Engineering**                 *S. clavuligerus*                  FK606                                                     Enhance                           \[[@B90-antibiotics-07-00041]\]
  *S. coelicolor*                           Actinorhodin                       Enhance                                                   \[[@B90-antibiotics-07-00041]\]   
  *S. rimosus*                              Oxytetracycline                    Enhance                                                   \[[@B91-antibiotics-07-00041]\]   
  **Co-cultures**                           *S. rimosus* MY02                  Antifungal activity                                       Enhance                           \[[@B36-antibiotics-07-00041]\]
  *S. coelicolor*                           Actinorhodin                       Enhance                                                   \[[@B37-antibiotics-07-00041]\]   
  *S. fradiae 007*                          Phenolic polyketides               Enhance                                                   \[[@B38-antibiotics-07-00041]\]   
  Marine *streptomycetes*                   See tables in reference            Cryptic                                                   \[[@B39-antibiotics-07-00041]\]   
  **Conditioning Morphology (PCD + MII)**   *S. cattleya*                      Tienamycin                                                Enhance                           \[[@B92-antibiotics-07-00041]\]
  *S. cinereoruber*                         Rodomycin                          Enhance                                                                                     
  *Saccharopolyspora erythraea*             Erithromycin                       Enhance                                                                                     
  *S. coelicolor*                           Actinorhodin                       Enhance                                                                                     

antibiotics-07-00041-t002_Table 2

###### 

Biosynthetic cluster specific methods and some successful examples of their enforcement.

  Methods                                   Microorganism                Product                                                          Effect                             Ref.
  ----------------------------------------- ---------------------------- ---------------------------------------------------------------- ---------------------------------- ----------------------------------
  **Engineering Self-Resistance**           *S. peucetius*               Doxorubicin, Daunorubicin                                        Enhance                            \[[@B93-antibiotics-07-00041]\]
  *S. avermitilis*                          Avermectin,                  Enhance                                                          \[[@B94-antibiotics-07-00041]\]    
  *S. coelicolor*                           Actinorhodin                 Enhance                                                          \[[@B95-antibiotics-07-00041]\]    
  **Regulatory Engineering**                                                                                                                                                 
  Delete repressor AbsA2\~P                 *S. coelicolor*              Actinorhodin, Undecylprodigiosin, Calcium-dependent antibiotic   Enhance                            \[[@B96-antibiotics-07-00041]\]
  Overexpress AverR/StrR                    *S. avermitilis*             Avermectin                                                       Enhance                            \[[@B97-antibiotics-07-00041]\]
  Overexpress AverR/StrR                    *S. griseous*                Streptomycin                                                     Enhance                            \[[@B98-antibiotics-07-00041]\]
  Overexpress SamR0484                      *S. ambofaciens*             Stambomicin A-D                                                  Cryptic                            \[[@B99-antibiotics-07-00041]\]
  Delete repressor *cmmRII*                 *S. griseus*                 Chromomycin                                                      Enhance                            \[[@B100-antibiotics-07-00041]\]
  Delete repressor AlpW                     *S. ambofaciens*             Alpomycin                                                        Enhance                            \[[@B101-antibiotics-07-00041]\]
  **Heterologous Expression**               *S. avermitilis*             Streptomycin                                                     Enhance                            \[[@B102-antibiotics-07-00041]\]
  *S. coelicolor*                           Chloramphenicol              Enhance                                                          \[[@B103-antibiotics-07-00041]\]   
  *S. coelicolor*                           Congocidine                  Enhance                                                          \[[@B103-antibiotics-07-00041]\]   
  *S. cyaneus*                              CECT 3335 laccase            Enhance                                                          \[[@B27-antibiotics-07-00041]\]    
  *S. lividans TK24*                        Mithramycin A                Enhance                                                          \[[@B104-antibiotics-07-00041]\]   
  *Streptomyces* sp.                        Neothioviridamide            Cryptic                                                          \[[@B105-antibiotics-07-00041]\]   
  Several wild-type                         Siamycin-I                   Cryptic                                                          \[[@B29-antibiotics-07-00041]\]    
  **Combinatorial Biosynthesis**            *S. albus J1074*             Novel paulomycin                                                 Cryptic                            \[[@B31-antibiotics-07-00041]\]
  See table 1 in ref.                                                                                                                     \[[@B30-antibiotics-07-00041]\]    
  **Conditioning Morphology (PCD + MII)**   *S. albus*                   Apigenin, Luteolin                                               Enhance                            \[[@B15-antibiotics-07-00041]\]
  *S. mobarensis*                           Microbial transglutaminase   Enhance                                                          \[[@B14-antibiotics-07-00041]\]    
